Ratings Alkem Laboratories Limited

Equities

Delayed NSE India S.E. Other stock markets 06:01:03 2025-07-09 am EDT			5-day change	1st Jan Change
4,805.40 ^INR	+0.09%		-0.76%	-14.59%

May. 30	Jefferies Adjusts Alkem Laboratories' Price Target to INR4,460 From INR4,580, Keeps at Underperform	MT
May. 29	Alkem Laboratories Limited, Q4 2025 Earnings Call, May 29, 2025

The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
With a 2025 P/E ratio at 26.01 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
The company's enterprise value to sales, at 4.17 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The group usually releases earnings worse than estimated.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	ALKEM LABORATORIES LIMITED				6.69B
	ELI LILLY AND COMPANY				698B
	JOHNSON & JOHNSON				375B
	ABBVIE INC.				335B
	NOVO NORDISK A/S				313B
	ROCHE HOLDING AG				259B
	NOVARTIS AG				240B
	ASTRAZENECA PLC				217B
	MERCK & CO., INC.				204B
	AMGEN INC.				160B
	Average				280.91B
	Weighted average by Cap.